{"id":"NCT01064414","sponsor":"Janssen Research & Development, LLC","briefTitle":"An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2011-12","completion":"2012-08","firstPosted":"2010-02-08","resultsPosted":"2013-05-27","lastUpdate":"2013-08-14"},"enrollment":272,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2","Renal Insufficiency"],"interventions":[{"type":"DRUG","name":"Canagliflozin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Canagliflozin 100 mg","type":"EXPERIMENTAL"},{"label":"Canagliflozin 300 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who have reduced kidney function.","primaryOutcome":{"measure":"Change in HbA1c From Baseline to Week 26","timeFrame":"Day 1 (Baseline) and Week 26","effectByArm":[{"arm":"Placebo","deltaMin":-0.03,"sd":0.09},{"arm":"Canagliflozin 100 mg","deltaMin":-0.33,"sd":0.09},{"arm":"Canagliflozin 300 mg","deltaMin":-0.44,"sd":0.089}],"pValues":[{"comp":"OG000 vs OG001","p":"0.012"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"25 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":106,"countries":["United States","Australia","Belgium","Brazil","Canada","France","Germany","India","Latvia","Malaysia","Mexico","New Zealand","Poland","Romania","Russia","South Africa","South Korea","Spain"]},"refs":{"pmids":["26580237","24786834","24517339"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":90},"commonTop":["Hypoglycaemia","Nasopharyngitis","Urinary tract infection","Diarrhoea","Oedema peripheral"]}}